Search

Your search keyword '"Courtney L. Andersen"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Courtney L. Andersen" Remove constraint Author: "Courtney L. Andersen"
27 results on '"Courtney L. Andersen"'

Search Results

1. Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

2. Data from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

Catalog

Books, media, physical & digital resources

3. Supplementary File 3 from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

4. Supplementary File 1 from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

5. Supplementary Figures from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

6. Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models

7. Abstract 4024: Combining selumetinib with BH3 mimetics enhances activity in MAPK-activated acute myeloid leukemia

8. The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer

9. Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

10. NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

11. AZD4573 Effectively Induces Apoptosis in r/r MCL As a Monotherapy or in Combination with Acalabrutinib

12. Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

14. Abstract 2957: A novel circulating tumor DNA (ctDNA) assay enables monitoring of disease progression and treatment response in disseminated preclinical hematologic cancer models

15. AZD4320 Is a Novel and Potent BCL-2/XL Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma

16. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells

17. Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges

18. Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

19. Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens

20. Abstract B23: The evolution of estrogen receptor signaling in the progression of endometriosis to endometriosis-associated ovarian cancer

21. Abstract B25: Hormone receptor expression and response in ovarian tumors of low malignant potential

22. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome

23. Abstract 862: WNT4 mediates endocrine response and resistance in invasive lobular carcinoma cell lines and patient tumor explants

24. Hormone response in ovarian cancer: time to reconsider as a clinical target?

25. Abstract 2103: Utilizing ER target genes as biomarkers of endocrine response in serous ovarian carcinoma

26. Abstract 94: Identifying biomarkers of estrogen response in models of serous ovarian cancer

27. Non-coding single nucleotide variants affecting estrogen receptor binding and activity